Review Article

iMedPub Journals
www.imedpub.com

Journal of HIV & Retrovirus
ISSN 2471-9676

2021
Vol.7 No.3:11

Three Months of Rifapentine Plus Isoniazid to Prevent Human Immuno Deficiency Virus Related Tuberculosis

Gudisa Bereda*

Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia

***Corresponding author**: Gudisa Bereda, Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia, Tel: +251919622717/ +251913118492; E-mail:gudisabareda95@gmail.com

Received date: October 28, 2021; **Accepted date:** November 11, 2021**; Published date:** November 18, 2021

Citation: Bereda G (2021) Three Months of Rifapentine Plus Isoniazid to Prevent Human Immuno Deficiency Virus Related Tuberculosis. J HIV Retrovirus Vol.7 No.3:11.

Abstract

Latent tuberculosis infection is delineated by an insistent immune reaction to Mycobacterium. tuberculosis antigens without confirmation of active infirmity. Subsequent weekly rifapentine and isoniazid are effective in the continuation phase of tuberculosis treatment in patients with a less bacillary refrain. Tuberculosis preventive treatment has dual considerable intentions: 1) defend people who are already infected with the tuberculosis bacterium from falling sick with active tuberculosis malady, and 2) ammunition people who are uninfected but at peril of tuberculosis liability from getting exposed in the first locale. The new regimen combines isoniazid and rifapentine and is bestowed in 12 once-weekly doses using directly observed therapy. A fixed-dose combination of rifapentine and isoniazid (300 mg/300 mg) that facilitates downhill administration of the 3-month Tuberculosis preventive treatment regimen of isoniazid and rifapentine in persons aged 13 years and above. The shorter duration of treatment with isoniazid and rifapentine and the greater rates of treatment completion make it more cost-effective in the long-term.

Keywords:

Human immunodeficiency virus; Isoniazid; Prevent; Rifapentine; Tuberculosis

Abbreviations

INH: Isoniazid; RPT: Rifapentine; LTBI: Latent TB Infection; M.TB: Mycobacterium Tuberculosis; FDC: Fixed-Dose Combination; DTG: Dolutegravir; IPT: Isoniazid Preventive Therapy; ARVs: Antiretrovirals; MIC: Minimum Inhibitory Concentration; DOT: Directly Observed Therapy; TB: Tuberculosis; INH-RPT: Isoniazid with Rifapentine; 3HP: Isoniazid and Rifapentine; 3RH: Rifampicin and Isoniazid; RIF: Rifampicin; TPT: Tuberculosis Preventive Therapy; PK: Pharmacokinetics.

Introduction

Mycobacterium tuberculosis, a bacterium transmitted by airborne droplet nuclei from patients with respiratory figures of the malady, causes TB, a contagious and implicitly calamitous malady [1]. LTBI is distinguished by the presence of immune feedbacks to M. TB infection without clinical confirmation of active TB infection by M. TB stays sophisticated to diagnose, which is why the genuine across-the board load is not well understood [2,3]. Clinically, LTBI is delineated by a persistent immune reaction to M. tuberculosis antigens without confirmation of active malady [4]. RIF and RPT belong to the rifamycin assemblage of medications that deed against mycobacteria by forbidding bacterial DNA-dependent RNA polymeras. Although, RPT is importantly has longer elimination half-life than RIF (>12 h vs. 2-3 h) [5,6]. Following oral ingestion, it reaches a plasma concentration much greater than the anticipated MIC and serum levels remain greater than the MIC for over 72 hours. Consumption with food (especially lipid-rich meal) accelerates the peak serum accumulation, in contrast to rifampicin that inevitably to be taken in a fasting state. Like distinctive rifamycins, rifapentine also has the implicit to antecedent adverse events, enclosing hepatotoxicity. The foundation of RPT PK in children extended the range of using the medication in children as well [7,8]. Tuberculosis preventive treatment has dual considerable intentions: 1) defend people who are already infected with the tuberculosis bacterium from falling ill with active tuberculosis malady, and 2) ammunition people who are uninfected but at peril of tuberculosis liability from getting exposed in the first locale. Preventive therapy is one of the best ways to keep individuals and families secure from TB, which in turn assists communities, become and remain TB free [9, 10]. The intention of LTBI treatment is to decrease the pitfall of reactivation [11,12]. The new regimen combines INH and RPT and is bestowed in 12 once-weekly doses using DOT [13,14]. RPT is an essential building block of shorter regimens for the treatment of TB infection, which are easier to complete than the longer regimens [15,16]

A one-month course of the antibiotic RPT combined with INH was just as effective as a nine-month course of INH in obviating the advancement of TB in people with HIV [17,18]. A FDC of RPT and INH (300 mg/300 mg) facilitates easier administration of the 3-month TPT regimen of 3HP in persons aged 13 years and above [19,20]. RPT belongs to a group of medicines called rifamycins and is the cornerstone of fresher short-course TPT. When combined with a second TB medicine, INH, RPT figures the 3HP regimen (taken once weekly for 12 weeks) and the 1HP

regimen (taken once a day for one month). The 3HP and 1HP regimens afford shorter discretion to the ancient strategy of meticulosity, called IPT, in which people take INH every day for amid six and 36 months [21,22]. RPT-based TPT is secure and well bearable owing to 3HP happens to charade least peril of hepatotoxicity than IPT [23]. The combination regimen of INH and RPT bestowed as 12 weekly DOT doses is recommended as an equivalent discretion to 9 months of daily self-supervised INH for treating LTBI in differently wholeness patients aged ≥ 12 years who have a prognosticate factor for higher likelihood of TB elaborating, which encloses current vulnerability to transmittable TB, transfiguration from negative to positive on a circuitous test for infection (i.e., interferon-γ release assay or tuberculin skin test), and radiographic sequences of curable pulmonary TB. HIV-infected patients who are differently healthy and are not taking ARV medications also are enclosed in this category [24]. NH/RPT-3 is a moderately new regimen, the simplicity and short duration of which afford substantial adjuration [25].

3HP and 3RH: Essence and Usage

3HP is a short-course TPT regimen that combines dual antibiotics active fight TB, INH and RPT. 3HP is taken once a week for 12 weeks (12 doses in 3 months). It has documented effective and secure for PLHIV and their household contacts >2 years old [26,27,21]. 3RH is taken once quotidian, for 12 weeks (90 doses in 3 months). The WHO LTBI guidance attestation released in precociously 2018 illustrates the 3RH regimen as an discretion preference to 6H, for treatment of LTBI in children and adolescents <15 years of age, in countries with great TB occurrence [27,26]. The short-course regimens 3HP and 3RH afford transparent merits in terms of confirmed adherence and completion rates owing to the shorter duration of treatment and the child-friendliness, FDC treatment preference avail for 3RH [26]. The 3HP regimen is simpler, shorter and necessitates fewer doses for patients [28]. Analogize to IPT, administering a shorter, weekly dose confines the load on TB and HIV programs. 3HP regimen could be cost-effective, thereby de-escalating the economic load of TB control exertions [29]. The shorter duration of treatment with 3HP and the greater rates of treatment completion make it voluminous cost-effective in the long-term [26]. Once a child-friendly and affordable FDC for HP becomes avail, 3HP can become the preferred regimen for TPT athwart entire ages. This will importantly facilitate release of TPT and corroborate a family-centered approach to LTBI management [26]. The group receiving combination regimen had a greater withdrawn rate owing to adverse effects (4.9% *vs.* 3.7%), hepatotoxicity was much lesser (0.4% *vs.* 2.7%). Thereupon the CDC recommended that the shorter INH-RPT regimen could be used to enhance adherence [30,31]. 3RH has better bearable, with fewer side effects and better adherence than 6 or 9 months of isoniazid lone [32,33]. A pediatric FDC that is both dispersible and palatable is recently avail for the 3RH regimen, while RPT is not yet avail in a child-friendly formulation and dosing is not yet known for children <2 years of age [34].

Potential Side Effects to the 12-Dose Regimen

Side effects in children are not ordinary. Isoniazid cause hepatitis/hepatotoxicity (symptoms include nausea, vomiting, abdominal pain, anorexia, yellow eyes/skin, light stools, dark urine), rash, peripheral neuropathy, hypersensitivity, mild CNS effects [35]. Rifapentine cause hepatitis/hepatotoxicity (symptoms enclose nausea, vomiting, abdominal pain, anorexia, yellow eyes/skin, light stools, dark urine), hypersensitivity reactions (perhaps enclose rash, dizziness, hypotension and flu-like symptoms, such as fever, muscle aches and headache), thromobocytopenia, neutropenia evidenced by easy bruising or bleeding, and orange discoloration of body fluids and soft contact lenses [35].

Contraindication of 3HP

INH-RPT is not recommended for the following patients such as children aged <2 years, because the security and pharmacokinetics of RPT have not been demonstrated for them; HIV-infected patients receiving antiretroviral treatment, because the drug interactions have not been measured; pregnant women or women anticipating to become pregnant during treatment, because safety in pregnancy is not well understood; and patients who have LTBI with plausible INH or RIF resistance. INH and RPT once weekly for 12 weeks (under DOT) is preferred regimen for children 5 and older should not be used in children younger than 2 owing to dearth of pharmacokinetic data or established dosing [36-38]

RIF and RPT are potent inducers of the cytochrome P450 oxidase system. Their administrations perhaps influence the pharmacokinetics of distinctive medications enclosing certain ARVs. For people living with HIV/AIDS, both 3HP and 3RH are secure to bestow with efavirenz-based ART without each dosing adjustments. In adults, 3HP is secure to bestow with DTG-based ART without every dosing adjustment. Both 3HP and 3RH de-escalate lopinavir-ritonavir and nevirapine levels. Thus, dosing adjustments are necessitated. So, RPT-based TPT is neither can be used coincidentally with lopinavir-ritonavir nor nevirapine. As a consequence, for HIV-infected children taking lopinavir-ritonavir, nevirapine, or dolutegravir, the preferred TPT regimen is represented by 6H (preferably with the dispersible formulation), which does not necessitate dose adjustment [39,40].

Discussion and Conclusion

M-TB, a bacterium transmitted by airborne droplet nuclei from patients with respiratory forms of the malady, antecedent TB, a transmittable and implicitly calamitous malady. Once a child-friendly and affordable FDC for HP becomes avail, 3HP can become the preferred regimen for TPT over all ages. This will substantially facilitate delivery of TPT and assist a family-centered approach to LTBI management. The shorter 3RH regimen for children affords advantages for patients and health systems. 3RH is better bearable, with fewer side effects and better adherence than 6 or 9 months of INH lone). The WHO

LTBI guidance attestation released in precociously 2018 illustrates the 3RH regimen as an discretion choice to 6H, for treatment of LTBI in children and adolescents <15 years of age, in countries with great TB occurrence.

Acknowledgments

The authors acknowledged Endnote-8, Google scholar, Medscape, Wikipedia, and PubMed.

Data Sources

Sources searched include Google Scholar, Research Gate, PubMed, NCBI, NDSS, PMID, PMCID, and Cochrane database. Search terms included: 3 months rifapentine and isoniazid treatment.

References

1. Tellier R, Li Y, Cowling BJ, Tang JW (2019) Recognition of aerosol transmission of infectious agents: a commentary. BMC Infect Dis. 19 (1):1-9.
2. Tavolara TE, Niazi MK, Ginese M, Piedra-Mora C, Gatti DM, et al. (2020) Automatic discovery of clinically interpretable imaging biomarkers for Mycobacterium tuberculosis super susceptibility using deep learning. EBioMedicine. 62:103094.
3. Li G, Li F, Zhao HM, Wen HL, Li HC, et al. (2017). Evaluation of a new IFN-γ release assay for rapid diagnosis of active tuberculosis in a high-incidence setting. Front Cell Infect Microbiol.7:117.
4. World Health Organization, “Guidelines on the management of latent tuberculosis infection,” 2015.
5. Tetali SR, Kunapaeddi E, Mailavaram RP, Singh V, Borah P, et al. (2020) Current advances in the clinical development of anti-tubercular agents. Int J Infect 125:101989.
6. Unissa AN, Hanna LE (2017) Molecular mechanisms of action, resistance, detection to the first-line anti-tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era. Int J Infect Dis. 105:96-107.
7. Rezhdo O (2018) Mechanistic Studies and Modeling of the Impact of Food on Oral Drug Absorption (Doctoral dissertation, Northeastern University).
8. Mutasim A. Ketoconazole Pharmacokinetics in Sudanese Patients with Mycetoma (Doctoral dissertation, UOFK).
9. ANYANGO BD. Evaluation of the effect of isoniazid preventive therapy among children living with HIV in OLA during children’s Hospital-Freetown, Sierra Leone (Doctoral dissertation, KeMU).
10. World Health Organization. Comprehensive TB guidelines for national tuberculosis program.
11. Chee CB, Reves R, Zhang Y, Belknap R (2018) Latent tuberculosis infection: Opportunities and challenges. BMJ Open Respir Res. 23(10):893-900.
12. Kiazyk S, Ball TB (2017) Tuberculosis (TB): Latent tuberculosis infection: An overview. Canada Communicable Disease Report. 43 (3-4):62.
13. Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, et al. (2020) Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Adv Sci. 15 (1):1-2.
14. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, et al. (2017) Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: A systematic review with network meta-analyses. BMC Infect Dis. 17(1):1-1.
15. World Health Organization. Target product profiles for tuberculosis preventive treatment. World Health Organization; 2020.
16. Stagg HR, Flook M, Martinecz A, Kielmann K, Zur Wiesch PA, et al. (2020) All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era. ERJ Open Research. 1;6 (4).
17. Khoury C. Treating latent tuberculosis: Efficacy of rifapentine plus isoniazid combination therapy vs. isoniazid monotherapy.
18. Lee A, Xie YL, Barry CE, Chen RY (2020) Current and future treatments for tuberculosis. BMJ. 2; 368.
19. World Health Organization. WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment.
20. World Health Organization. South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection.
21. TO AA. Rifapentine.
22. Borah P, Deb PK, Venugopala KN, Al-Shar'i NA, Singh V, et al. (2021) Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host-Directed Therapies. Curr Top Med Chem.1; 21 (6):547-70.
23. Hosseini Z, Eftkhar H, Aghamolaei T, Ebadi A, Nedjat S, et al. (2019) Psychometric properties of the scale for non-adherence to antiretroviral medication (NAME) among HIV-infected patients. Arch Public Health. 77 (1):1-7.
24. World Health Organization. South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection.
25. Sterling T, Villarino M, Borisov A, et al. (2011) Three months of rifapentine and isoniazid for latent tuberculosis infection. NEJM. 365 (23):2155–66.
26. Innovations CP. Short-course Treatment Regimens to Prevent TB: 3HP and 3RH.
27. Cardenas V. Violet Chihota2 Johns Hopkins University, USA 2The Aurum Institute, Johannesburg, South Africa 3University of California at San Francisco, USA.
28. Rewari BB, Kumar A, Mandal PP, Puri AK (2021) HIV TB coinfection-perspectives from India. Expert Rev Respir Med. 20:1-20.
29. Okada RC, Barry PM, Skarbinski J, Chitnis AS (2018) Epidemiology, detection, and management of tuberculosis among end-stage renal disease patients. Infect Drug Resist. 39 (11):1367-74.
30. Motta I, Calcagno A, Bonora S (2018) Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? Expert opinion on drug metabolism & toxicology. 14 (1):59-82.
31. Bares SH, Swindells S (2020) Latent Tuberculosis and HIV Infection. Current Infectious Disease Reports. 22:1-8.
32. Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D’Ambrosio L, et al. (2018) New drugs and perspectives for new anti-tuberculosis regimens. J Cell Physiol. 24 (2):86-98.
33. World Health Organization. Report of the meeting to review the paediatric antituberculosis drug optimization priority list.

34. READER IN. Carlton KK Lee, PharmD, MPH (2012) The Harriet Lane Handbook of Pediatric Antimicrobial Therapy E-Book: Mobile Medicine Series. 15:362.

35. Mehtani NJ, Puryear S, Pham P, Dooley KE, Shah M (2021) Infectious Diseases Learning Unit: Understanding Advances in the Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency Virus. In Open forum infectious diseases (Vol. 8, No. 8, p. ofab319). US: Oxford University Press.

36. Lam E, Schaefer J, Zheng R, Zhan T, Kraft WK (2020) Twice-daily do ravirine overcomes the interaction effect from once-weekly rifapentine and isoniazid in healthy volunteers. Clinical and translational science. 13 (6):1244-50.

37. Motta I, Calcagno A, Bonora S (2018) Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: A tool for treatment optimization?. Expert opinion on drug metabolism & toxicology. 14 (1):59-82.

38. Namdar R, Peloquin CA (2018) Drugs for tuberculosis. In Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions (pp. 221-253). Humana Press, Cham.

39. Davies G, Peloquin C (2020) Clinical Pharmacology of the Anti-Tuberculosis Drugs. In Clinical Tuberculosis (pp. 175-201). CRC Press.

40. Ramanathan MR, Howell CK, Sanders JM (2019) Drugs in tuberculosis and leprosy. In Side Effects of Drugs Annual (Vol. 41, pp. 321-338).